Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Immunity, Inflammation and Disease is Scopus-indexed (Q2, CiteScore 5.4), WoS SCIE, DOAJ. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 2050-4527Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Immunology and Allergy | 99 / 234 | 57th | Q2 |
| Immunology | 111 / 243 | 54th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2013–present, best quartile Q2, CiteScore 5.4.
Immunity, Inflammation and Disease is Q2 in Immunology and Allergy (rank 99 of 234) and Q2 in Immunology (rank 111 of 243), by CiteScore 2025.
Immunity, Inflammation and Disease is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.4, which places it in quartile Q2 at the 57th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.851, quartile Q2, with an H-index of 43.
The publisher lists an article processing charge of about US$3,300 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Immunity, Inflammation and Disease is published by John Wiley and Sons Inc. Its ISSN is 2050-4527.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Immunity, Inflammation and Disease has an h-index of 51 and a 2-year mean of 4.07 citations per paper (OpenAlex). Its Scopus CiteScore is 5.4, quartile Q2. On 2-year citations it ranks #55 of 231 Scopus journals in Immunology and Allergy.
Immunity, Inflammation and Disease published 224 papers in 2025; its busiest recent year was 2024 with 369. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2026), authors are most often from China (65.5%), Iran (7.4%) and India (4.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 28 retracted papers are recorded (14.4 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.